Abstract
Antiresorptive pharmacologic interventions for the prevention and treatment of osteoporosis are discussed. These interventions include estrogen; calcitonin; biphosphonates; and selective estrogen receptor modulators and their use in postmenopausal osteoporosis, steroid-induced osteoporosis, and osteoporosis in men. The effects of antiresorptive therapy on bone mineral density, biomarkers of bone turnover, and fracture risk are discussed.
MeSH terms
-
Bone Density
-
Bone Remodeling
-
Bone Resorption / prevention & control*
-
Bone and Bones / injuries
-
Calcitonin / therapeutic use
-
Calcium / therapeutic use
-
Diphosphonates / therapeutic use
-
Estrogens / therapeutic use
-
Female
-
Fractures, Bone / prevention & control
-
Humans
-
Male
-
Osteoporosis / drug therapy*
-
Osteoporosis, Postmenopausal / drug therapy
-
Osteoporosis, Postmenopausal / prevention & control
-
Randomized Controlled Trials as Topic
-
Vitamin D / therapeutic use
Substances
-
Diphosphonates
-
Estrogens
-
Vitamin D
-
Calcitonin
-
Calcium